Metástasis de carcinoma de células en anillo de sello al cuello uterino / Metastasis of signet-ring cell carcinoma of the cervix

Las metástasis de carcinomas extragenitales al útero es rara y el compromiso al cuello uterino es excepcional, especialmente del tipo histológico de carcinoma de células en anillo de sello. Se presentan tres casos encontrados en 240 adenocarcinomas cervicales (1,25 por ciento) diagnosticados entre 1979-2012. Dos casos se presentaron en pacientes de 48 y 56 años originados en carcinomas lobulillares infiltrantes de la mama diagnosticados previamente. La primera paciente está viva a 19 meses del diagnóstico ginecológico y la segunda falleció a los 14 meses, siendo en ambas un hallazgo histológico incidental en cirugías realizadas por patología ginecológica benigna. El tercer caso se presentó en una paciente de 43 años que debutó por metrorragia y tumor cervical y fue originado en un carcinoma gástrico infiltrante difuso, encontrado en forma sincrónica y fallece a los 2 meses del diagnóstico. Se revisan los criterios diagnósticos entre metástasis y carcinoma primario de células en anillo de sello del cuello uterino y el aporte al diagnóstico de la histología convencional, la inmunohistoquímica y la tipificación molecular de HPV. Conclusión: Se concluye que la metástasis de carcinoma de células en anillo al cuello uterino es rara y el pronóstico es malo. La citoreducción y la quimioterapia podría tener un rol para casos seleccionados de carcinomas metastásicos de origen mamario y que estos casos no deberían ser considerados un evento preterminal.

The uterine metastatic involving of extragenital carcinomas is rare, especially the signetring cell type. Three of such a cases were found in 240 cases of adenocarcinomas of uterine cervix (1.25 percent) diagnosed between 1979-2012. Two of these cases occurred in patients aged 48 and 56 years with infiltrating lobular carcinomas arising in the breast previously diagnosed. The first patient is alive at 19 months after diagnosis and the second is deceased at 14 months after diagnosis. In both cases, the metastasis to the cervix was an incidental histological finding in surgeries performed by benign gynecological pathology. The third case was identified in a 43-years old patient who debuted with metrorrhagia and cervical tumor which was originated in a diffuse infiltrating gastric carcinoma that was found synchronously and she is dead at 2 months after diagnosis. The diagnostic criteria between metastases and primary cervix carcinoma of signet ring cells and the contribution to the diagnosis of conventional histology, immunohistochemistry and molecular typing of HPV are reviewed. The metastasis of signet ring cell carcinoma to the uterine cervix is rare and the survival is poor. Conclusion: The role of cytoreduction and chemotherapy for selected cases of metastasis from breast carcinomas should be considered and in such a case the gynecological involvement should not be considered a preterminal event.

A study on expression pattern of cyclooxygenase-2 in carcinoma of cervix.

Objective: The purpose of the present study was to determine the differential expression pattern of cyclooxygenase-2 (COX-2) in patients of carcinoma of uterine cervix and its correlation with tumor differentiation and lymphovascular invasion. Materials and Methods: Seventy (70) cases of cervical carcinoma were included (20 in-situ, 42 invasive squamous cell, and 8 cases of adenocarcinoma). Formalin-fixed paraffin-embedded tissue sections were stained by Hematoxylin and Eosin. Immunohistochemistry for COX-2 were performed on these blocks. Results: A higher expression of COX-2 was seen in invasive squamous cell carcinoma than in in-situ carcinoma (P = 0.002). Five out of eight cases of adenocarcinoma showed strong positivity for COX-2 antibody. Among the histopathological correlates, tumor differentiation did not show a positive correlation (P = 0.717), while lymphovascular invasion was associated with positive staining in majority of the cases (P = 0.001). Conclusion: Expression of COX-2 is more in cases of invasive than in in-situ carcinoma. Adenocarcinomas showed a strong expression of COX-2. A positive association of COX-2 expression and the presence of lymphovascular emboli were found in the present study. COX-2 inhibitors need to be studied as a therapeutic adjunct for the treatment of carcinoma cervix.

Clinicopathological study of small cell carcinoma of the cervix / 医学研究生学报

Objective:To study the clinical and pathological features of small cell carcinoma of cervix.(SCCC).Methods:Clinical data,pathological changes and immunohistochimical findings were reviewed in 7 cases of small cell cervical carcinoma(SCCC),and immunohistochemical staining was performed for VEGF in 4 cases of SCCC.Results:The average age was 37 years in 7 patients,and the main symtoms were vaginal bleeding.Under microscope,tumor cells showed oat or intermediate cell type,Three tumors were associated with other forms of carcinoma: squamous cell carcinoma,endometrial carcinoma,poor-differentiated adenocarcinoma.Immunohistochemical staining showed neuroendocrine differentiation and VEGF.Their FIGO staging was stage Ⅰ_b in 2 cases,stage Ⅱ in 2 cases,stage Ⅲ in 2 cases.In the 5 patients with follow-up data,4 were dead and 1 was in following up.Conclusion:Small cell carcinoma of the cervix has stated an extremely aggressive biological behavior with minimal survival chances and a rapid and fatal clinical course.

The Efficacy of Tumor Markers SCCA and CA 125 in Patients with Squamous Cell Carcinoma of Uterine Cervix / 대한부인종양콜포스코피학회잡지

To evaluate the efficacy and diagnostic and prognostic significance of two tumor markers (SCCA, CA 125) in patient with squamous cell carcinoma of uterine cervix, the authors studied 215 patients with squamous cell carcinoma in situ and invasive carcinoma from September 1993 to November 1996. Both tumor markers were measured coincidently in 215 patients preopera-tively and in 70 cases of benign gynecologic disease for control group. Serum SCCA level of 2.5 ng/ml and CA 125 level of 35.0 U/ml were determined as cut-off levels. The results were as follows: 1. The pretreatment positive rate of SCCA in patient group were 35.8 %(77/215) and 5.7 %(4/70) in control group. 2. The mean values and positive rates of SCCA according to clinical stage were 1.44+/-3.59 ng/ml(8.7 %) for stage 0, 3.81+/-10.22 ng/ml(23 %) for stage I, 8.54+/-15.23 ng/ml(51.3 %) for stage II, 35.54+/-38.34 ng/ml(70.0 %) for stage III, 22.49+/-36.06 ng/ml(75.0 %) for stage IV, 40.33+/-58.66 ng/ml(66.7 %) for recurrent cancer, respectively. The mean SCCA value and positive rate were significantly increased stepwise by clinical stage from stage I to stage III (P0.05). 5. The result of preoperative serum levels of SCCA can be characterized by 35.8 % sensitivity, 94.3 % specificity, 95.1 % positive predictive value, 32.4 % negative predictive value, 49.5 % diagnostic efficiency, and with 21.9 %, 82.8 %, 79.7 %, 25.7 %, 36.8 % respectively for CA 125. Between these two tumor markers, the result of SCCA was more valuable than the other in sensitivity, positive predictive value, negative predictive value and diagnostic efficiency. The results indicate that measurement of SCCA and/or CA 125, have little efficacy in the early detection of squamous cell carcinoma considering it's low rate of positivity in preinvasive and early stage of invasive squamous cell carcinoma. However, in patients with advanced stage invasive carcinoma, measurement of serum SCCA is useful in prediction of prognosis and in early detection of recurrence, and concomitant measurements of SCCA and CA 125 may be more useful in determining prognosis, therapeutic response, and early detection of recurrence than measurement of SCCA alone.

Detection of Human Papillomavirus DNA by In Situ Hybridization using Biotinylated DNA Probes in Cervical Intraepithelial Neoplasias and Squamous Cell Carcinomas

The authors examined 9 condylomas, 26 cervical intraepithelial neoplasms(CIN) and 22 invasive squamous cell carcinomas for the presence of human papillomavirus(HPV) DNA sequences by DNA-DNA in situ hybridization. In situ hybridization revealed target HPV DNA sequences mostly in the nuclei of the superficial cells from epithelium which contained either maturation or koilocytotic atypias. With the use of biotinylated HPV DNA probes 6/11, 16/18 and 31/33/35, 42 of the 57(73.7%) were positive with HPV-6/11, 23 with HPV-16/18, 32 with HPV-31/33/35 and 18 with two or more mixed probes. HPV-31/33/35 was wht most prevalent in CIN and invasive squamous cell carcinomas, follwed by HPV-16/18. The incidence of HPV DNA increased from 66.7% to 86.4% with increasing severity of the lesions from condylomas to invasive squamous cell carcinomas. Flat condyloma was most freuently accompanied by CIN.

Carcinoembryonic antigen in patients with carcinoma of cervix.

Seventy two patients with different stages of cervical cancer have attended the Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, for radiation therapy. Before treatment, 38.9 percent of these patients had serum carcinoembryonic antigen (CEA) level above normal range (normal=0-3.38 ng/ml). Among these patients, 48 cases had serial serum CEA determinations through 11-36 months after prognosis within 1 year after treatment. The patients who had pretreatment CEA levels between 3.38-10 ng/ml had better prognosis if CEA declined to normal level within 1-2 months after treatment, since only 15.4 percent had recurrence within 3 years. The patients who had decreasing CEA levels after treatment but increased upon follow up always had distance metastasis. The patients who had adenocarcinoma had slightly higher levels of CEA than those with squamous cell carcinoma. The CEA levels did not correlate with staging of the disease, but rather depend on the natural properties of individual’s cancer cells. The usefulness of serial CEA determinations was found only in the patients who had increased CEA before treatment. We suggest that the serum CEA determination should be performed in every patient with carcinoma of cervix and serially thereafter in those who have pretherapy increment, i.e. immediately or 1-2 months after radiation therapy and later every 3-6 months.